Silence Therapeutics plc 8-K

What Happened
Silence Therapeutics plc filed a Form 8-K (Item 7.01) on June 23, 2026, to disclose an updated corporate presentation reflecting certain business updates. The presentation has been furnished as Exhibit 99.1 to the 8-K and is posted in the "Investors" section of the company website (silence-therapeutics.com/investors). The filing was signed by Iain Ross, Interim Principal Executive Officer and Chairman of the Board.

Key Details

• Filing date: June 23, 2026 (Form 8-K, Item 7.01, Regulation FD disclosure).
• Document furnished: Corporate presentation dated June 23, 2026 (Exhibit 99.1).
• Availability: Posted on the company’s investor website at silence-therapeutics.com/investors.
• Company note: Content on the company website is not incorporated by reference into the 8-K.

Why It Matters
This is a Regulation FD disclosure ensuring material business updates are made publicly available to all investors at the same time. While the 8-K does not report financial results or executive changes, investors should review the updated presentation for any new information on the company’s strategy, programs, timelines or partnerships that could affect valuation or investment decisions.